步长制药(603858) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥2,804,745,065.33, a decrease of 9.02% compared to the same period last year[3]. - Total profit for the quarter reached ¥270,987,497.81, an increase of 176.88% year-on-year[3]. - Net profit attributable to shareholders was ¥240,622,461.09, reflecting a year-on-year increase of 195.44%[3]. - The basic earnings per share for the quarter was ¥0.2282, up 201.85% from the previous year[3]. - Total operating revenue for the first three quarters of 2025 was RMB 8,468,581,319.22, a slight decrease of 0.54% compared to RMB 8,514,403,594.83 in the same period of 2024[16]. - Net profit for the first three quarters of 2025 reached RMB 791,128,418.90, significantly up from RMB 217,875,832.22 in 2024, representing an increase of 263.36%[16]. - The total comprehensive income attributable to the parent company for the current period was ¥868,272,719.71, significantly higher than ¥312,794,509.27 in the previous period, marking an increase of about 177.5%[17]. - Basic and diluted earnings per share for the current period were both ¥0.8208, up from ¥0.2870 in the previous period, representing an increase of approximately 186.4%[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥19,570,305,482.49, a 1.25% increase from the end of the previous year[4]. - The total assets of the company as of September 30, 2025, were RMB 19,570,305,482.49, an increase from RMB 19,328,509,108.36 at the end of 2024[13]. - The total liabilities decreased to RMB 9,498,225,530.17 from RMB 9,520,425,198.24, indicating a reduction in financial leverage[14]. - The total equity attributable to shareholders increased by 3.49% to ¥10,572,989,443.73 compared to the previous year[4]. - The equity attributable to shareholders of the parent company increased to RMB 10,572,989,443.73 from RMB 10,216,464,921.09, reflecting a stronger financial position[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥815,091,912.71, an increase of 16.20%[3]. - The net cash flow from operating activities for the first three quarters of 2025 was ¥815,091,912.71, an increase from ¥701,464,029.30 in the same period of 2024, reflecting a growth of approximately 16.2%[19]. - The net cash flow from investing activities was -¥353,958,586.25 for the first three quarters of 2025, worsening from -¥194,586,275.00 in the same period of 2024[20]. - The net cash flow from financing activities was -¥412,424,487.33 in the first three quarters of 2025, compared to -¥241,904,375.55 in 2024, showing a decline of approximately 70.6%[20]. - The cash inflow from financing activities totaled ¥1,503,116,701.92 in the first three quarters of 2025, down from ¥1,973,312,494.35 in 2024, indicating a decrease of about 23.8%[20]. - The cash outflow for purchasing goods and services was ¥2,063,410,259.46 in the first three quarters of 2025, slightly higher than ¥1,969,430,996.01 in the same period of 2024, reflecting an increase of about 4.5%[19]. - The company reported a total of ¥4,236,249.91 in cash received from other investment activities in the first three quarters of 2025, down from ¥5,308,128.25 in 2024, indicating a decrease of approximately 20.2%[19]. Operational Efficiency - The net cash flow from operating activities for the first three quarters of 2025 was ¥815,091,912.71, an increase from ¥701,464,029.30 in the same period of 2024, reflecting a growth of approximately 16.2%[19]. - Accounts receivable decreased to RMB 442,244,978.97 from RMB 893,298,254.41, indicating improved collection efficiency[12]. - Inventory stood at RMB 4,516,810,317.61, slightly down from RMB 4,624,384,936.53, reflecting better inventory management[12]. - The company's R&D expenses for the first three quarters of 2025 were RMB 153,627,979.11, down from RMB 180,201,501.97 in 2024, suggesting a potential shift in focus[16]. Acquisitions - The company has completed acquisitions of Tonghua Hong Pharmaceutical Co., Ltd. and Jilin Tiancai Pharmaceutical Co., Ltd., contributing to the profit growth[7].